[go: up one dir, main page]

MX2016014404A - Preparacion liquida acuosa que contiene acido 2-amino-3-(bromobenzoil) fenilacetico. - Google Patents

Preparacion liquida acuosa que contiene acido 2-amino-3-(bromobenzoil) fenilacetico.

Info

Publication number
MX2016014404A
MX2016014404A MX2016014404A MX2016014404A MX2016014404A MX 2016014404 A MX2016014404 A MX 2016014404A MX 2016014404 A MX2016014404 A MX 2016014404A MX 2016014404 A MX2016014404 A MX 2016014404A MX 2016014404 A MX2016014404 A MX 2016014404A
Authority
MX
Mexico
Prior art keywords
liquid preparation
aqueous liquid
rhinitis
bromobenzoyl
amino
Prior art date
Application number
MX2016014404A
Other languages
English (en)
Inventor
A Baklayan George
E Padilla Angeliqueo
Sawa Shirou
Fujita Shuhei
Original Assignee
Bausch & Lomb Pharma Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32767329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016014404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb Pharma Holdings Corp filed Critical Bausch & Lomb Pharma Holdings Corp
Publication of MX2016014404A publication Critical patent/MX2016014404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una preparación líquida acuosa de la presente invención que contiene ácido 2-amino-3-(4-bromobenzoil)fenilacético o su sal farmacológicamente aceptable o un hidrato del mismo, un polímero de tipo alcohol de poliéter de alquilarilo tal como Tiloxapol o un éster de ácido graso de polietilenglicol tal como un monoestearato de polietilenglicol es estable. Una modalidad de dicha preparación líquida no incluye conservante alguno. Dicha preparación líquida acuosa en forma de gotas oculares es útil para el tratamiento de blefaritis, conjuntivitis, escleritis e inflamación post-operatoria. Asimismo, la preparación líquida acuosa de la presente invención en forma de una gota nasal es útil para el tratamiento de la rinitis alérgica y rinitis alérgica (por ejemplo, rinitis crónica, rinitis hipertrófica, pólipo nasal, etc.).
MX2016014404A 2003-01-21 2015-05-05 Preparacion liquida acuosa que contiene acido 2-amino-3-(bromobenzoil) fenilacetico. MX2016014404A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003012427 2003-01-21
US14/269,692 US9144609B2 (en) 2003-01-21 2014-05-05 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
PCT/IB2015/000887 WO2015170177A1 (en) 2003-01-21 2015-05-05 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid

Publications (1)

Publication Number Publication Date
MX2016014404A true MX2016014404A (es) 2017-10-27

Family

ID=32767329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014404A MX2016014404A (es) 2003-01-21 2015-05-05 Preparacion liquida acuosa que contiene acido 2-amino-3-(bromobenzoil) fenilacetico.

Country Status (15)

Country Link
US (9) US8129431B2 (es)
EP (1) EP1586316B1 (es)
JP (1) JP4500261B2 (es)
KR (1) KR101059711B1 (es)
CN (1) CN100341498C (es)
AT (1) ATE393627T1 (es)
BE (1) BE2011C027I2 (es)
CA (2) CA2944832C (es)
DE (2) DE122011100019I1 (es)
ES (1) ES2301964T3 (es)
FR (1) FR11C0031I2 (es)
HU (1) HUS1100022I1 (es)
MX (1) MX2016014404A (es)
PT (1) PT1586316E (es)
WO (2) WO2004064828A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
DE122011100019I1 (de) 2003-01-21 2011-11-03 Senju Pharma Co Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
CA2560559C (en) 2004-11-05 2013-07-02 Senju Pharmaceutical Co., Ltd. Aqueous intraocular penetration-promoting eye drop
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
JP2009524692A (ja) * 2006-01-25 2009-07-02 アーシエックス， インコーポレイテッド ドライアイのための処方物および方法
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
BRPI0808410A2 (pt) * 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
CN101754748A (zh) * 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
CN101313899B (zh) * 2007-06-01 2012-02-29 北京德众万全药物技术开发有限公司 一种含有溴芬酸钠的眼用药物组合物
CN101965183A (zh) * 2008-02-21 2011-02-02 伊斯塔药品公司 作为佐剂的眼用nsaid
EP2420223B1 (en) * 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
CN102711748A (zh) * 2009-11-11 2012-10-03 微型实验室有限公司 用于治疗青光眼和高眼压症的前列腺素化合物和非甾体抗炎药的药物组合
KR102075173B1 (ko) * 2011-01-18 2020-02-07 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물
JP6012231B2 (ja) * 2011-04-08 2016-10-25 ロート製薬株式会社 ブロムフェナク含有組成物
EP2701680B1 (en) 2011-04-29 2018-10-31 Allergan, Inc. Sustained release latanoprost implant
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
MX348418B (es) 2011-10-12 2017-06-12 Bausch & Lomb Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
JP6353365B2 (ja) * 2012-09-27 2018-07-04 千寿製薬株式会社 水性液剤
JP6161500B2 (ja) * 2012-10-05 2017-07-12 ロート製薬株式会社 ブロムフェナク含有組成物
CA2890182C (en) * 2012-11-19 2020-10-06 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤
WO2014120293A1 (en) * 2013-01-31 2014-08-07 Sentiss Pharma Pvt.Ltd. Ophthalmic formulations
KR20150110775A (ko) * 2013-01-31 2015-10-02 센주 세이야꾸 가부시키가이샤 안정한 수성액제
EP3010485A1 (en) 2013-06-19 2016-04-27 Sentiss Research Center Stable bromfenac solution
WO2015046281A1 (ja) * 2013-09-26 2015-04-02 参天製薬株式会社 安定化された２－アミノ－３－（４－ブロモベンゾイル）フェニル酢酸含有水性組成物
WO2015087267A2 (en) * 2013-12-12 2015-06-18 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
US10130639B1 (en) 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
CN106404952B (zh) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 一种溴芬酸钠滴眼液有关物质的测定方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880130A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
US2880138A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
CH577461A5 (es) 1975-08-13 1976-07-15 Robins Co Inc A H
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
HU199072B (en) * 1987-09-11 1990-01-29 Syntex Inc Antimicrobal conserving composition and process for production of compositions for oculist purpuses
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
JPH0283323A (ja) * 1988-09-20 1990-03-23 Zeria Pharmaceut Co Ltd 安定な酪酸リボフラビン水溶液
JPH02124819A (ja) 1988-11-01 1990-05-14 Mitsubishi Kasei Corp 経口コレステロール低下剤
JPH05223052A (ja) 1992-02-06 1993-08-31 Kanematsu Eng Kk 波浪エネルギ−を利用した電流発生装置及びこの電流発生装置が備えられた水素ガス発生装置
US5496811A (en) 1992-08-28 1996-03-05 Pharmos Corp. Submicron emulsions as ocular drug delivery vehicles
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP1163906A3 (en) 1994-03-15 2003-05-21 Senju Pharmaceutical Co., Ltd. Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
ES2079320B1 (es) 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
AU3609795A (en) 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
JPH11228404A (ja) * 1997-12-11 1999-08-24 Senju Pharmaceut Co Ltd 安定な水性点眼剤
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6369112B1 (en) * 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
KR20020042667A (ko) 1999-09-06 2002-06-05 우에노 도시오 안질환 예방 및 치료제
AR030345A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
JP2002308764A (ja) * 2001-02-09 2002-10-23 Taisho Pharmaceut Co Ltd 眼科用医薬組成物
DE122011100019I1 (de) * 2003-01-21 2011-11-03 Senju Pharma Co Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
WO2005046700A1 (ja) * 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
JP5223052B2 (ja) 2010-05-21 2013-06-26 春誠 鈴木 コーキングガン
MX348418B (es) * 2011-10-12 2017-06-12 Bausch & Lomb Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
CA2890182C (en) * 2012-11-19 2020-10-06 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid

Also Published As

Publication number Publication date
DE602004013420D1 (de) 2008-06-12
US20140142183A1 (en) 2014-05-22
US8927606B1 (en) 2015-01-06
ES2301964T3 (es) 2008-07-01
EP1586316A1 (en) 2005-10-19
FR11C0031I2 (fr) 2012-03-16
EP1586316B1 (en) 2008-04-30
DE602004013420T2 (de) 2009-06-04
US8754131B2 (en) 2014-06-17
KR101059711B1 (ko) 2011-08-29
CN1700913A (zh) 2005-11-23
US8129431B2 (en) 2012-03-06
ATE393627T1 (de) 2008-05-15
WO2015170177A1 (en) 2015-11-12
KR20050092691A (ko) 2005-09-22
US9561277B2 (en) 2017-02-07
EP1586316A4 (en) 2007-06-27
US8669290B2 (en) 2014-03-11
CA2944832A1 (en) 2015-11-12
US8871813B2 (en) 2014-10-28
US20140243413A1 (en) 2014-08-28
US9144609B2 (en) 2015-09-29
BE2011C027I2 (es) 2023-03-07
PT1586316E (pt) 2008-05-28
US20150025149A1 (en) 2015-01-22
JP4500261B2 (ja) 2010-07-14
HK1083468A1 (en) 2006-07-07
CA3043910A1 (en) 2015-11-12
HUS1100022I1 (hu) 2017-04-28
US20130090384A1 (en) 2013-04-11
US20050239895A1 (en) 2005-10-27
CA2944832C (en) 2019-10-08
US20150011634A1 (en) 2015-01-08
CN100341498C (zh) 2007-10-10
US20120115957A1 (en) 2012-05-10
US20140235721A1 (en) 2014-08-21
WO2004064828A1 (ja) 2004-08-05
JPWO2004064828A1 (ja) 2006-05-18
US20070287749A1 (en) 2007-12-13
DE122011100019I1 (de) 2011-11-03
US8497304B2 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
MX2016014404A (es) Preparacion liquida acuosa que contiene acido 2-amino-3-(bromobenzoil) fenilacetico.
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
BRPI0714399B8 (pt) composição farmacêutica líquida oral
BR112015005995A2 (pt) formulações líquidas de apixaban
RU2011101713A (ru) Фармацевтическая композиция
EA201170553A1 (ru) Новые липиды и композиции для доставки лекарственных средств
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
CY1112401T1 (el) Παραγωγα πυριδαζινης
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
FR2906140B1 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
AR063027A1 (es) Derivados de sulfonamida
BR9908479A (pt) Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
DK1459739T3 (da) Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
RU2012117141A (ru) Композиции олопатадина и способы их применения
WO2015087267A3 (en) Stable bromfenac ophthalmic solution
EA201591910A1 (ru) Стабильный раствор бромфенака
EA201490127A1 (ru) Офтальмологический раствор, содержащий гиалуроновую кислоту или ее соль и пропиленгликоль
EE04869B1 (et) Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors